NextCure, Inc. — Director's Dealing 2019

May 9, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-08

Reporting Person: CANAAN X L.P. (10% Owner)
Reporting Person: Canaan Partners X LLC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (445866)		Direct
Series A-2 Preferred Stock	$		Common Stock (743110)		Direct
Series A-3 Preferred Stock	$		Common Stock (729599)		Direct
Series B-1 Preferred Stock	$		Common Stock (285867)		Direct

Footnotes

F1: The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.

F2: The reported securities are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.